APA (7th ed.) Citation

TK, C., T, P., L, A., M, B., C, S., B, Z., . . . RJ, M. (2023). Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. The New England journal of medicine, 388(19), 1767. https://doi.org/10.1056/NEJMoa2212851

Chicago Style (17th ed.) Citation

TK, Choueiri, et al. "Cabozantinib Plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma." The New England Journal of Medicine 388, no. 19 (2023): 1767. https://doi.org/10.1056/NEJMoa2212851.

MLA (9th ed.) Citation

TK, Choueiri, et al. "Cabozantinib Plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma." The New England Journal of Medicine, vol. 388, no. 19, 2023, p. 1767, https://doi.org/10.1056/NEJMoa2212851.